ProShare Advisors
BOLT icon

ProShare Advisors’s Bolt Biotherapeutics BOLT Stock Holding History

ProShare Advisors’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-512
Closed -$50K – 2219
2021
Q4 		$50K Buy
+512
New +$97.2K ﹤0.01% 2284

Other funds holding BOLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ESCM
Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

ProShare Advisors's BOLT Position: Q1 2022 in Review

ProShare Advisors sold out of Bolt Biotherapeutics (BOLT) in Q1 2022, closing a stake of 512 shares — an estimated $50K sold.

ProShare Advisors first reported a position in BOLT in Q4 2021 and held it in 1 quarter. The position peaked at $50K in Q4 2021. 65 funds tracked by Wall St. Rank hold BOLT as of Q1 2022.

  • ProShare Advisors reported no remaining Bolt Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • ProShare Advisors sold 512 Bolt Biotherapeutics shares in Q1 2022, an estimated $50K.
  • ProShare Advisors first reported a position in Bolt Biotherapeutics in Q4 2021 and held it in 1 quarter.
  • ProShare Advisors's Bolt Biotherapeutics position peaked at $50K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.